Kynexis is at the forefront of developing precision therapeutics for brain diseases, particularly focusing on cognitive impairment associated with schizophrenia (CIAS). Their approach involves utilizing biomarkers to advance potential first-in-class treatments. By leveraging extensive data, Kynexis aims to identify and stratify patients based on the underlying causal human biology of the disease. The company is targeting KAT-I...
Kynexis is at the forefront of developing precision therapeutics for brain diseases, particularly focusing on cognitive impairment associated with schizophrenia (CIAS). Their approach involves utilizing biomarkers to advance potential first-in-class treatments. By leveraging extensive data, Kynexis aims to identify and stratify patients based on the underlying causal human biology of the disease. The company is targeting KAT-II, a crucial enzyme in the kynurenine pathway. KYN-5356, their lead candidate, is a first-in-class small molecule known for its potency and high selectivity for KAT-II.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.